bluebird bio Inc and Bristol-Myers Squibb Co to Provide Regulatory Update on Idecabtagene Vicleucel - Conference Call
שיחת ועידה bluebird bio Inc
bluebird bio Inc Conference call will be held on 13/05/2020. During the earnings conference call's session bluebird bio Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact bluebird bio Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad potential application in these areas. We believe that gene therapy for severe genetic diseases has the potential to change the way these patients are treated by correcting the underlying genetic defect that is the cause of their disease, rather than offering treatments that only address their symptoms. Our clinical programs in severe genetic diseases include our LentiGlobin® product candidate to treat transfusion-dependent ?-thalassemia, or TDT, and to treat severe sickle cell disease, or severe SCD, and our Lenti-D(TM) product candidate to treat cerebral adrenoleukodystrophy, or CALD.קרא עוד שיחת ועידה